Why Is Januvia So Hard to Find? [Explained for 2026]

If you've been trying to fill your Januvia prescription and hitting roadblocks, you're not alone. Despite Januvia (sitagliptin) being one of the most widely prescribed type 2 diabetes medications in the United States — with nearly 8 million prescriptions filled in 2022 alone — millions of patients still struggle to access it consistently. So what's going on?

The short answer: Januvia isn't in an official FDA shortage, but a combination of high costs, insurance hurdles, and no true generic alternative creates very real access barriers for patients. Let's break it down.

Is Januvia in a Shortage in 2026?

No — as of 2026, Januvia is not listed on the FDA Drug Shortage Database. Merck, Januvia's manufacturer, produces adequate supply to meet demand. The problem isn't a supply chain failure; it's an access problem rooted in cost and insurance coverage.

However, there was a notable period around 2022 when FDA investigators found nitrosamine impurities (specifically Nitroso-STG-19, or NTTP) in some sitagliptin samples. This triggered quality concerns and contributed to regional supply disruptions. That issue has since been resolved, but it's part of why patients and providers became attuned to availability issues with sitagliptin products.

Why Is Januvia So Expensive and Hard to Afford?

The biggest barrier for most patients isn't pharmacy stock — it's price. The average retail price for a 30-day supply of Januvia 100 mg is $600–$700 without insurance. That's because Januvia remains a brand-name-only medication with no true generic equivalent available in most pharmacies today.

Here's the nuanced situation with Januvia generics in 2026:

Zituvio (sitagliptin free base) — FDA-approved in October 2023 by Zydus Pharmaceuticals. It contains sitagliptin but in a different chemical form (free base vs. phosphate salt). It is NOT interchangeable with Januvia and requires a separate prescription.

Generic Januvia (sitagliptin phosphate) — Merck's key sitagliptin patent expires November 24, 2026. Settlement deals with generic manufacturers allow entry as early as May 2026 under certain conditions. True generics are expected, but aren't yet widely available.

This means most patients are stuck paying full brand-name price unless they have commercial insurance or qualify for assistance programs — which effectively makes Januvia "hard to find" at an affordable price, even if the physical supply is available on shelves.

What Role Does Insurance Play?

Most employer-sponsored health plans and Medicare Part D plans do cover Januvia, but coverage isn't automatic. Common insurance hurdles include:

Prior authorization (PA): Many plans require your doctor to submit documentation proving other medications (like metformin) were tried first.

Step therapy: Insurers may require patients to try less expensive alternatives before approving Januvia.

High copays: Even with insurance, Januvia can land on Tier 3 formulary, resulting in copays of $50–$150 or more per month.

Medicare Part D gap (donut hole): Seniors on Medicare can face higher out-of-pocket costs when their total drug spending falls in the coverage gap.

Are Some Pharmacies More Likely to Have Januvia in Stock?

While Januvia is generally available at major chain pharmacies (CVS, Walgreens, Walmart, Rite Aid) and most independent pharmacies, stock levels can vary. Some smaller independent pharmacies may not keep Januvia on hand regularly due to its high acquisition cost and lower turnover compared to generic alternatives. If your regular pharmacy is out, calling ahead saves significant time — or better yet, using a service like medfinder to have pharmacies checked for you.

What About the Nitrosamine Contamination Issue?

In 2022, the FDA discovered the presence of nitrosamine impurities in some sitagliptin samples. Nitrosamines are potentially carcinogenic compounds that have triggered recalls and shortages in several drug categories in recent years. Merck and other manufacturers took corrective action, and the issue has been resolved. Januvia currently on pharmacy shelves meets FDA safety standards.

What Is the Future for Januvia Availability?

The outlook is improving for patients. The key sitagliptin patent expires November 24, 2026, and settlement agreements allow generic manufacturers to enter the market as early as May 2026. Once true generic Januvia (sitagliptin phosphate) becomes widely available, prices are expected to fall 80–85%, potentially bringing the cost down to $50–$100 per month. That shift alone will dramatically improve access for uninsured and underinsured patients.

How Can medfinder Help?

If you're struggling to locate Januvia at a pharmacy near you, medfinder can help. medfinder calls pharmacies in your area to check which ones can fill your prescription, then texts you the results. You don't have to spend time on hold with multiple pharmacies — medfinder does the legwork for you.

Once you find a pharmacy with Januvia in stock, check out our guide on how to save money on Januvia to make sure you're getting the best possible price.

Key Takeaways

Januvia is NOT in an official FDA shortage in 2026 — supply is generally available.

The main access barrier is cost: $600–$700/month retail without insurance or savings programs.

No true generic equivalent (Januvia phosphate salt) is yet widely available, though generic entry is expected in 2026.

Insurance prior authorization and step therapy requirements add another layer of difficulty.

medfinder can help you locate which pharmacies near you have Januvia in stock.